We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.
Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.